Ongoing Clinical Trials
FLOW: Effect of Semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
FLOW is a multi-center, international, randomized, double-blind, parallel-group, placebo-controlled trial comparing the medication, Semaglutide 1.0 mg, versus placebo, both administered subcutaneously once weekly, and added to standard-of-care in subjects with Type-2 Diabetes and pre-existing Chronic Kidney Disease. Objectives includes: to demonstrate that Semaglutide delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality compared to placebo; and to compare the effect of treatment with Semaglutide versus placebo, both added to standard-of-care in subjects with type 2 diabetes and chronic kidney disease with regards to cardiovascular morbidity, peripheral artery disease, glycemic control, body weight, blood pressure and safety.
PCOS: The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome - A Pilot Randomized Controlled Trial
Polycystic ovary syndrome (PCOS) is a common hormone disorder affecting 10 to 15 percent of reproductive aged women. Affected individuals may have irregular menstrual periods, excessive hair growth, acne and/or cysts on their ovaries identified on ultrasound. PCOS is associated with infertility, diabetes and heart disease. The Endocrine Society recommends exercise to treat PCOS, although the most effective exercise prescription is unclear. This project is a pilot randomized controlled trial assessing two exercise interventions – high-intensity interval training (HIIT) versus continuous aerobic exercise training versus no exercise. The goal of this pilot study is to assess participant recruitment, dropout and adherence with a long-term exercise intervention in PCOS. An additional primary objective is to obtain preliminary estimates of the treatment effect on ovulation, a marker of fertility, to inform a future more definitive trial. Secondary objectives are to assess the impact of these exercise interventions on reproductive, anthropometric, metabolic and quality-of-life outcomes.
PERLage: Preventing Early Renal Loss (Follow-up Study)
PERLage is a PERL follow-up study. The PERLage Study is being conducted to investigate the long-term effects of Allopurinol treatment on kidney function in persons with Type-1 Diabetes, and mild to moderate diabetic kidney disease. It also aims to study the long-term effects of Allopurinol treatment on cardiovascular and eye complications. This is an observational, multicenter, prospective, post-RCT (Randomized Control Trial) cohort study.
REMIT-IDegLira: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes with IDegLira
Approximately 1 in 10 adults in Canada currently have diagnosed diabetes. Recent research suggests that it may be possible to reverse type 2 diabetes or put it into remission using intensive lifestyle therapy and short-term combination drug therapy with injectable insulin and oral diabetes medications. This trial will test whether a short treatment with a combined basal insulin degludec and Liraglutide (IDegLira), metformin, and lifestyle is able to achieve prolonged diabetes remission.
Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
Semaglutide is a medicine that may be prescribed in some countries to treat Type-2 Diabetes. A completed study showed that Semaglutide reduced the risk of cardiovascular events in patients with T2DM. In the SELECT clinical trial, the study doctors will check to see if Semaglutide may reduce the risk of future cardiovascular events in patients without diabetes, but with overweight or obesity.